Caduet

Caduet is a brand name of amlodipine/atorvastatin, approved by the FDA in the following formulation(s):

CADUET (amlodipine besylate; atorvastatin calcium - tablet; oral)

• 
  Manufacturer: PFIZER
  
  Approval date: January 30, 2004
  
  Strength(s): EQ 10MG BASE;EQ 10MG BASE, EQ 10MG BASE;EQ 20MG BASE, EQ 10MG BASE;EQ 40MG BASE, EQ 10MG BASE;EQ 80MG BASE ^[RLD], EQ 5MG BASE;EQ 10MG BASE, EQ 5MG BASE;EQ 20MG BASE, EQ 5MG BASE;EQ 40MG BASE, EQ 5MG BASE;EQ 80MG BASE
  


• 
  Manufacturer: PFIZER
  
  Approval date: July 29, 2004
  
  Strength(s): EQ 2.5MG BASE;EQ 10MG BASE, EQ 2.5MG BASE;EQ 20MG BASE, EQ 2.5MG BASE;EQ 40MG BASE
  

Has a generic version of Caduet been approved?

No. There is currently no therapeutically equivalent version of Caduet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Caduet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable oral CI-981 formulation and process of preparing same
  Patent 5,686,104
  Issued: November 11, 1997
  Inventor(s): Mills; Nancy & Muhammad; Nouman A. & Weiss; Jay & Nesbitt; Russell U.
  Assignee(s): Warner-Lambert Company
  An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.
  
  Patent expiration dates:
  
  
  • November 11, 2014
    
    ✓ 
    Patent use: METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
    ✓ 
    Drug product
  
  
  
  • May 11, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
  Patent 5,969,156
  Issued: October 19, 1999
  Inventor(s): Briggs; Christopher A. & Jennings; Rex A. & Wade; Robert & Harasawa; Kikuko & Ichikawa; Shigeru & Minohara; Kazuo & Nakagawa; Shinsuke
  Assignee(s): Warner-Lambert Company
  Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents.
  
  Patent expiration dates:
  
  
  • July 8, 2016
    
    ✓ 
    Drug substance
  
  
  
  • January 8, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Stable oral CI-981 formulation and process for preparing same
  Patent 6,126,971
  Issued: October 3, 2000
  Inventor(s): Mills; Nancy & Muhammad; Nouman A. & Weiss; Jay & Nesbitt; Russell U.
  Assignee(s): Warner-Lambert Company
  An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.
  
  Patent expiration dates:
  
  
  • January 19, 2013
    
    ✓ 
    Drug product
  
  
  
  • July 19, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Therapeutic combination
  Patent 6,455,574
  Issued: September 24, 2002
  Inventor(s): Jan; Buch
  Assignee(s): Pfizer Inc.
  This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
  
  Patent expiration dates:
  
  
  • August 11, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
  
  

See also...

• Caduet Consumer Information (Drugs.com)
• Caduet Consumer Information (Wolters Kluwer)
• Caduet Consumer Information (Cerner Multum)
• Caduet Advanced Consumer Information (Micromedex)
• Amlodipine/Atorvastatin Consumer Information (Wolters Kluwer)
• Amlodipine and atorvastatin Consumer Information (Cerner Multum)
• Amlodipine and atorvastatin Advanced Consumer Information (Micromedex)